Phathom Pharmaceuticals (PHAT)

• Market cap: $344M
• 1 day: -10.02%
• 5 days: -26.16%
• 1 month: -5.18%
• 3 months: -36.18%
• 6 months: -72.78%
• Year to date: -32.61%
• 1 year: -49.90%
• 5 years: -83.59%
• 10 years: -79.92%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

119% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 27

64% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 22

8% more funds holding

Funds holding: 133 [Q3] → 144 (+11) [Q4]

9.05% less ownership

Funds ownership: 106.56% [Q3] → 97.51% (-9.05%) [Q4]

42% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 7 (-5) [Q4]

59% less capital invested

Capital invested by funds: $1.32B [Q3] → $541M (-$774M) [Q4]

91% less call options, than puts

Call options by funds: $455K | Put options by funds: $5.2M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 143% upside
• Avg. target: $23 359% upside
• High target: $28 467% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Needham Joseph Stringer 0% 1-year accuracy 0 / 5 met price target	467% upside $28	Buy Reiterated	2 Apr 2025
Goldman Sachs Paul Choi 50% 1-year accuracy 3 / 6 met price target	143% upside $12	Neutral Maintained	10 Mar 2025
HC Wainwright & Co. Matthew Caufield 31% 1-year accuracy 20 / 64 met price target	467% upside $28	Buy Reiterated	7 Mar 2025